![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Patel, AJ Smith, KL Chapman, AE Fletcher, JA Kemp, GR Marshall, RJ Hargreaves, W Ryecroft, LL Iversen and SD Iversen
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, Great Britain.
A novel series of 5-amino-1,4-benzodiazepin-2-one derivatives (amidines), which contain a cationic solubilizing group and which are antagonists for the cholecystokinin (CCK)-B receptor, have been identified. Optimization of this series led to the identification of an azabicyclononane amidine, L-740,093 [N-[(3R)-5-(3- azabicyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2- oxo- 1H-1,4- benzodiazepin-3-yl]-N'-(3-methylphenyl)urea], that bound with high affinity of CCK-B receptors from guinea pig cerebral cortex (IC50 of 0.1 nM) and had a CCK-B/CCK-A receptor selectivity of 16,000. In comparison, L-365,260 had 85-fold lower affinity (8.5 nM) and was only 87-fold selective for CCK-B over CCK-A receptors. L-740,093 bound with high affinity to guinea pig gastrin receptors in vitro (IC50 of 0.04 nM). Electrophysiological studies on slices of rat ventromedial hypothalamic nucleus showed that L-740,093 produced rightward shifts of the concentration-response curve for the CCK-B receptor agonist pentagastrin (Kb of 0.06 nM). L-740,093 blocked pentagastrin-induced gastric acid secretion in anesthetized rats with a 50% inhibitory dose of 0.01 mg/kg, intraperitoneally, showing 100-fold greater activity, compared with L-365,260 (50% inhibitory dose of 1 mg/kg, intraperitoneally). An ex vivo binding assay in mice was used to investigate the interaction of L-740,093 with central CCK binding sites. After intravenous administration, L-740,093 inhibited ex vivo binding dose dependently, with a 50% effective dose of 0.2 mg/kg. These studies demonstrate that L-740,093 is the most potent and selective CCK- B antagonist yet described and that it has excellent central nervous system penetration.
This article has been cited by other articles:
|
|
 |
|
  M Ogasa, Y Miyazaki, S Hiraoka, S Kitamura, Y Nagasawa, O Kishida, T Miyazaki, T Kiyohara, Y Shinomura, and Y Matsuzawa Gastrin activates nuclear factor {kappa}B (NF{kappa}B) through a protein kinase C dependent pathway involving NF{kappa}B inducing kinase, inhibitor {kappa}B (I{kappa}B) kinase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptor Gut, June 1, 2003; 52(6): 813 - 819. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Hiraoka, Y. Miyazaki, S. Kitamura, M. Toyota, T. Kiyohara, Y. Shinomura, N. Mukaida, and Y. Matsuzawa Gastrin induces CXC chemokine expression in gastric epithelial cells through activation of NF-{kappa}B Am J Physiol Gastrointest Liver Physiol, September 1, 2001; 281(3): G735 - G742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Thommesen, K. Norsett, A. K. Sandvik, E. Hofsli, and A. Lagreid Regulation of Inducible cAMP Early Repressor Expression by Gastrin and Cholecystokinin in the Pancreatic Cell Line AR42J J. Biol. Chem., February 11, 2000; 275(6): 4244 - 4250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wank I. CCK receptors: an exemplary family Am J Physiol Gastrointest Liver Physiol, April 1, 1998; 274(4): G607 - G613. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
